BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

82.41 -0.04 (-0.05%)

Streaming Delayed Price Updated: 3:03 PM EDT, Jul 22, 2026 Add to My Watchlist

Price and Volume

Volume	730,684
Open	82.47
Bid (Size)	82.34 (200)
Ask (Size)	82.47 (100)
Prev. Close	82.45
Today's Range	81.02 - 82.86
52wk Range	42.09 - 93.42
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

Today 7:30 EDT

From BridgeBio Pharma, Inc.

Via GlobeNewswire

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

July 13, 2026

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

Performance

YTD	+5.3%	+5.3%
1 Month	+19.6%	+19.6%
3 Month	+8.2%	+8.2%
6 Month	+6.8%	+6.8%
1 Year	+79.5%	+79.5%

More News

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

July 09, 2026

Via Chartmill

BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗

May 07, 2026

Via Chartmill

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

July 02, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Via The Motley Fool

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

July 01, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

June 28, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

June 22, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

May 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗

May 13, 2026

Via MarketBeat

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

May 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

May 11, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 08, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

May 07, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in May and June Investor Conferences

May 06, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

May 06, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

May 05, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

May 04, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

April 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗

April 28, 2026

Via The Motley Fool

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

April 28, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 82.41

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 07/22/26 03:03 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 13.23B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.